Revance Therapeutics, a biotechnology company developing topical and injectable botulinum toxin products, has elected Julian S. Gangolli, the president of GW Pharmaceuticals North America, to join its Board of Directors and serve as a member of the company’s Audit Committee, effective July 1, 2016.
Gangolli, a former member of Allergan’s executive management team, brings more than 20 years of senior management experience to the board. “We are thrilled to add Julian Gangolli to our Board of Directors. Julian has a distinguished track record successfully overseeing product and brand strategy, commercialization campaigns and business development activities in specialties such as dermatology, neurology, and ophthalmology,” said Dan Browne, president and CEO of Revance. “He had direct involvement in the extraordinary growth of the botulinum toxin market. He will be invaluable as we continue to progress toward regulatory approval and commercialization of RT002 injectable, our novel neurotoxin product candidate, and further expand our pipeline into a variety of therapeutic areas.”
Concurrent with Mr. Gangolli’s appointment, James Glasheen, PhD, will step down from the board. “Since joining our board in 2004, Jim has been a valued advisor, seeing us from our early development phase, through the initial public offering and now into late-stage development of our neurotoxin,” said Browne. “Through Technology Partners, he was an important early investor in the company and is now making a natural transition to other venture opportunities. We appreciate the strategic guidance and financial acumen he brought to our Audit Committee and boardroom and thank him for his many years of contributions.”